CVRx (CVRX) Net Income towards Common Stockholders (2020 - 2026)
CVRx's (CVRX) quarterly Net Income towards Common Stockholders came in at -$13.1 million in Q1 2026, up 4.69% year-on-year from -$12.5 million in Q1 2025, and down 9.94% quarter-over-quarter from -$11.9 million in Q4 2025.
CVRx (CVRX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
CVRx's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$13.1 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 4.69% year-over-year to -$13.1 million in Q1 2026; TTM through Mar 2026 was -$52.7 million, a 2.14% decrease from a year earlier, with the FY2025 full-year figure at -$53.3 million, up 11.12% from the prior year.
- Net Income towards Common Stockholders eased to -$13.1 million in Q1 2026 per CVRX's latest filing, from -$11.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$9.0 million in Q3 2023 and bottomed at -$22.2 million in Q1 2024.
- The 5-year median for Net Income towards Common Stockholders is -$11.7 million (2023), against an average of -$12.3 million.
- Across the five-year window, Net Income towards Common Stockholders plunged 95.06% in 2024 and surged 37.95% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$10.5 million in 2022, then rose by 14.43% to -$9.0 million in 2023, then declined by 18.27% to -$10.7 million in 2024, then fell by 11.92% to -$11.9 million in 2025, then declined by 9.94% to -$13.1 million in 2026.
- Per Business Quant, the three latest CVRX Net Income towards Common Stockholders figures stand at -$13.1 million (Q1 2026), -$11.9 million (Q4 2025), and -$12.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | CVRx | 128.88 Mn | 56.58 Mn | 12.88 Mn | -13.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.12 Mn |
| Dec 31, 2025 | -11.93 Mn |
| Sep 30, 2025 | -12.87 Mn |
| Jun 30, 2025 | -14.74 Mn |
| Mar 31, 2025 | -13.77 Mn |
| Dec 31, 2024 | -10.66 Mn |
| Sep 30, 2024 | -13.10 Mn |
| Jun 30, 2024 | -14.03 Mn |
| Mar 31, 2024 | -22.19 Mn |
| Dec 31, 2023 | -9.02 Mn |
| Sep 30, 2023 | -9.01 Mn |
| Jun 30, 2023 | -11.65 Mn |
| Mar 31, 2023 | -11.37 Mn |
| Dec 31, 2022 | -10.54 Mn |
| Sep 30, 2022 | -9.83 Mn |
| Jun 30, 2022 | -11.07 Mn |
| Mar 31, 2022 | -9.99 Mn |
| Dec 31, 2021 | -10.57 Mn |
| Sep 30, 2021 | -6.13 Mn |
| Jun 30, 2021 | -17.75 Mn |